Actuate Therapeutics Announces Participation in Key Investor Conferences
Actuate Therapeutics, Inc. (NASDAQ: ACTU), a pioneering company in cancer treatment, is excited to reveal its participation in major upcoming investor conferences. Focused on tackling high-impact, hard-to-treat cancers, Actuate specializes in developing therapies through the inhibition of glycogen synthase kinase-3 beta (GSK-3?). Daniel Schmitt, the President and CEO of Actuate, will represent the company at these events, opening opportunities for in-depth discussions with investors and stakeholders.
BIO CEO & Investor Conference Details
The first notable event is the BIO CEO & Investor Conference. This conference will feature an "IPO Class of 2024 Panel" alongside scheduled one-on-one meetings. Taking place in a vibrant New York setting, this event promises to provide insights into the latest advancements in biotechnology and investment opportunities in the therapeutic space.
Format and Schedule
The BIO CEO & Investor Conference is set for February 10, 2025. This format allows for direct interactions with management, fostering a deeper understanding of Actuate's strategies and objectives.
B. Riley Precision Oncology & Radiopharma Conference
Following the BIO event, Actuate will also participate in the B. Riley Precision Oncology & Radiopharma Conference slated for February 28, 2025. This event will include a fireside chat and additional one-on-one meetings, allowing attendees to engage in meaningful conversations regarding the company’s developments and initiatives.
Opportunities for Personalized Discussions
Investors attending the B. Riley event are encouraged to reach out to their representatives to arrange personal meetings with Actuate's management team. Such interactions often shed light on strategic plans and help build investor confidence in the company’s direction.
About Actuate Therapeutics, Inc.
Actuate Therapeutics is at the forefront of clinical-stage biopharmaceutical development, concentrating on innovative therapies for challenging cancer types. The company is advancing its lead investigational drug, elraglusib, which acts as a GSK-3? inhibitor. This novel approach targets critical molecular pathways involved in tumor growth and also aims to counteract resistance mechanisms often seen with conventional treatments like chemotherapy.
The Role of Elraglusib
Elraglusib is designed to enhance anti-tumor immunity by inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulating various immune checkpoints. By impacting these pathways, Actuate's therapeutic efforts could provide new hope for patients battling difficult cancers, positioning the company as a notable player in the biopharmaceutical landscape.
Investor Relations and Contact Information
For further inquiries and to stay updated on Actuate's developments, interested parties can contact the company directly. The reach out to investor relations can provide valuable insights and further information regarding the firm’s evolution and its impact on the healthcare sector.
Contact for Investor Relations
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Frequently Asked Questions
What are the upcoming conferences Actuate Therapeutics will attend?
Actuate Therapeutics will participate in the BIO CEO & Investor Conference and the B. Riley Precision Oncology & Radiopharma Conference.
Who is the CEO of Actuate Therapeutics?
Daniel Schmitt is the President and Chief Executive Officer of Actuate Therapeutics.
What is elraglusib?
Elraglusib is Actuate's lead investigational drug, a GSK-3? inhibitor aimed at treating difficult cancers.
How can investors schedule meetings with Actuate management?
Investors can arrange one-on-one meetings with Actuate's management through their conference representatives at the respective events.
Where can I find more information about Actuate's therapies?
Additional information about Actuate Therapeutics and its therapies is available on the company's official website.
